newsfilter
← Latest News
GlobeNewswire·

Revolution Medicines Presents Updated Phase 1/2 Data for RASONQUE® (daraxonrasib) Plus Chemotherapy in First-Line Metastatic Pancreatic Cancer at ENA 2026

  • Revolution Medicines announced updated results from the Phase 1/2 RMC-GI-102 study showing deep & durable responses for RASONQUE (daraxonrasib) combined with gemcitabine & nab-paclitaxel (GnP) as a first-line treatment for metastatic pancreatic adenocarcinoma.
  • As of September 28, 2026, 61 patients in the first-line cohort received the combination therapy with a median follow-up of 18.3 months.
  • The updated analysis reported a confirmed objective response rate of 60.7%, including complete responses in 8.2% of patients.
  • Disease control was observed in 90.2% of patients, with a median duration of response of 11.1 months.
  • Median progression-free survival was 12.8 months, while the 12-month overall survival rate was 76.6%.
  • The safety profile remained consistent with known profiles for RASONQUE & GnP, with dermatologic toxicity occurring in 86% of patients & stomatitis in 57%.
  • These findings support the ongoing Phase 3 RASolute 303 trial, which evaluates RASONQUE in combination with GnP versus GnP alone in treatment-naïve metastatic PDAC patients.
  • The data will be presented as a late-breaking oral session at the EORTC-NCI-AACR Symposium in Barcelona on November 20, 2026.
  • RASONQUE is currently FDA-approved for patients with metastatic PDAC who have received prior systemic therapy, while the combination for first-line treatment holds Breakthrough Therapy Designation.
Company
Revolution Medicines, Inc.
Keywords
Nasdaq:RVMD, Revolution Medicines, Inc., #RVMD, RVMD, oncology, cancer, RAS, KRAS